Press Releases
May 6, 2021
Summary ToggleIntellia Therapeutics Announces First Quarter 2021 Financial Results
Plan to report initial safety and activity data from Phase 1 study of NTLA-2001, a potentially curative single-dose therapy for transthyretin amyloidosis (ATTR), in mid-2021 On track to submit an IND or IND-equivalent in mid-2021 to advance NTLA-5001 for acute myeloid leukemia (AML) Expect to
Apr 29, 2021
Summary ToggleIntellia Therapeutics to Hold Conference Call to Discuss First Quarter 2021 Earnings and Company Updates
CAMBRIDGE, Mass. , April 29, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo , will present its first quarter 2021 financial results and operational
Apr 27, 2021
Summary ToggleIntellia Therapeutics Announces Presentations at the 24th American Society of Gene and Cell Therapy Annual Meeting
Updated preclinical data will be presented on CRISPR/Cas9-mediated targeted gene insertion to treat alpha-1 antitrypsin deficiency (AATD) CAMBRIDGE, Mass. , April 27, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), today announced the presentation of new data from its
Apr 12, 2021
Summary ToggleIntellia Therapeutics Names Georgia Keresty, Ph.D., M.P.H., to Board of Directors
CAMBRIDGE, Mass. , April 12, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo , today announced the appointment of Georgia Keresty , Ph.D.,
Mar 30, 2021
Summary ToggleIntellia Therapeutics’ Investigational CRISPR Treatment NTLA-2001 Receives European Union Orphan Drug Designation for ATTR Amyloidosis
CAMBRIDGE, Mass. , March 30, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo , announced today that the European Commission (EC) has granted orphan
Mar 25, 2021
Summary ToggleIntellia Therapeutics Presents New Data on Expanded Cell Engineering Capabilities Utilizing Base Editors
CAMBRIDGE, Mass. , March 25, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA) will present the first preclinical data set on its novel cytosine deaminase base editor technology at the seventh Cold Spring Harbor Laboratory (CSHL) virtual scientific meeting on Nucleic Acid
Mar 10, 2021
Summary ToggleIntellia Therapeutics Presents Preclinical Proof of Concept for CRISPR-based In Vivo Editing of Bone Marrow at Keystone eSymposium
Demonstrates the promise of Intellia’s proprietary non-viral delivery system for in vivo genome editing of tissues outside the liver, with applications to inherited blood disorders such as sickle cell disease - Observed durable, multidose editing of whole bone marrow and hematopoietic stem cells
Feb 25, 2021
Summary ToggleIntellia Therapeutics Announces Fourth Quarter and Full-Year 2020 Financial Results
Expects to report initial data from Phase 1 study of NTLA-2001, a potentially curative single-course therapy for transthyretin amyloidosis (ATTR), in 2021 On track to submit an IND or IND-equivalent in mid-2021 for NTLA-5001 for the treatment of acute myeloid leukemia (AML) Intends to submit an IND
Feb 18, 2021
Summary ToggleIntellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2020 Earnings and Company Updates
CAMBRIDGE, Mass. , Feb. 18, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo , will present its fourth quarter and full-year 2020 financial results
Jan 7, 2021
Summary ToggleIntellia Therapeutics Highlights Strategic Priorities and Anticipated Development Milestones for 2021
Continued advancement of global Phase 1 study of NTLA-2001, a potentially curative single-course therapy for transthyretin amyloidosis (ATTR) Anticipates submitting an IND or IND-equivalent in mid-2021 for NTLA-5001 for the treatment of acute myeloid leukemia (AML) Expects to submit an IND or
